Uncategorized
Age-Related Pharmacokinetics of Temocapril: Clinical Insights for Hypertension Management in Young and Elderly Patients
Temocapril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used in the treatment of essential hypertension. This study evaluates the impact of age on the pharmacokinetics of temocapril and its active metabolite, temocaprilat, in young and elderly hypertensive patients. Subjects were divided into two groups (≤40 years and ≥69 years) and received both single and multiple oral doses of temocapril hydrochloride. Pharmacokinetic parameters were assessed following a single dose and at steady state after repeated administration. Results demonstrated that steady state was achieved within one week in both age groups. Elderly patients exhibited significantly higher systemic exposure to temocaprilat, as indicated by increased area under the curve (AUC) and reduced renal clearance, likely due to age-related declines in kidney function. However, other pharmacokinetic parameters, including peak concentration and time to peak, showed no significant differences. These findings suggest that while pharmacokinetic variations exist, they do not necessitate routine dose adjustment. Nonetheless, a lower initial dose may be advisable in elderly patients to reduce the risk of first-dose hypotension. Overall, the study supports the safe and effective use of temocapril across different age groups when individualized treatment strategies and appropriate monitoring are applied.
Introduction: Temocapril in Hypertension Management
Hypertension remains one of the most prevalent chronic conditions worldwide and a major risk factor for cardiovascular morbidity and mortality. Persistently elevated blood pressure is closely associated with an increased risk of stroke, myocardial infarction, heart failure, and chronic kidney disease. Effective management of hypertension is therefore essential to reduce long-term complications and improve patient outcomes. Among the various therapeutic classes available, angiotensin-converting enzyme (ACE) inhibitors play a central role due to their proven efficacy, tolerability, and additional protective effects on the heart and kidneys.
Temocapril is a long-acting ACE inhibitor widely used in the treatment of mild to moderate essential hypertension. Like other drugs in its class, temocapril works by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This mechanism leads to vasodilation, reduced aldosterone secretion, and ultimately lower blood pressure. Importantly, temocapril is administered as a prodrug and is metabolized in vivo to its active diacid form, temocaprilat, which is primarily responsible for its pharmacological activity. Understanding the pharmacokinetics of both temocapril and temocaprilat is critical for optimizing therapeutic outcomes.
Fig. 1 Temocapril in Hypertension Management: Age-Related Pharmacokinetics and Clinical Implications.
Pharmacokinetics—encompassing absorption, distribution, metabolism, and excretion—plays a key role in determining drug efficacy and safety. Variability in these processes can significantly influence drug exposure, therapeutic response, and the risk of adverse effects. One of the most important sources of variability is patient age. Physiological changes associated with aging, such as reduced renal function, altered hepatic metabolism, and changes in body composition, can affect how drugs are processed in the body. As a result, elderly patients often exhibit different pharmacokinetic profiles compared to younger individuals.
These age-related differences are particularly relevant in the context of antihypertensive therapy. Elderly patients are not only more likely to have hypertension but are also more vulnerable to drug-related adverse events, such as excessive blood pressure reduction and first-dose hypotension. Therefore, understanding whether drugs like temocapril require dose adjustments in older populations is essential for safe and effective treatment. Investigating the pharmacokinetics of temocapril across different age groups provides valuable insights that can guide clinical decision-making and support individualized therapy in hypertension management.
Study Objective and Design
Understanding how age influences drug disposition is essential for optimizing antihypertensive therapy, particularly when prescribing ACE inhibitors such as temocapril. The primary objective of this study was to evaluate the potential impact of age on the pharmacokinetics of temocapril and its active metabolite, temocaprilat, in patients with mild to moderate essential hypertension. By comparing younger and elderly populations under controlled conditions, the study aimed to determine whether clinically relevant differences exist that could necessitate dose adjustments or special precautions in older patients.
To achieve this objective, the study enrolled male and female patients diagnosed with essential hypertension, defined by diastolic blood pressure (DBP) values ranging from 95 to 114 mmHg. Participants were stratified into two distinct age groups to allow for a clear comparison: a younger cohort aged 40 years or below, and an elderly cohort aged 69 years or older. Each group consisted of 18 subjects, ensuring balanced representation and sufficient statistical power to detect differences in pharmacokinetic parameters.
The study was conducted in two sequential parts to assess both single-dose and steady-state pharmacokinetics. In Part I, all participants received a single oral dose of 20 mg temocapril hydrochloride following an overnight fast. This phase was designed to characterize the initial absorption, metabolism, and elimination profiles of the drug and its active metabolite without the influence of accumulation. Blood samples were collected at predefined time points to determine plasma concentrations of temocapril and temocaprilat, enabling the calculation of key pharmacokinetic parameters such as maximum concentration (Cmax), time to reach Cmax (Tmax), and area under the concentration–time curve (AUC).
In Part II, the same subjects entered a multiple-dose phase in which they received 20 mg of temocapril hydrochloride once daily for seven consecutive days. This regimen allowed researchers to evaluate steady-state pharmacokinetics and drug accumulation. Trough plasma concentrations were measured prior to each daily dose to monitor the approach to steady state, while full pharmacokinetic profiling was conducted after the final dose. Additionally, urine samples were collected over a 24-hour period following both the single dose and the last dose to assess renal excretion and calculate renal clearance (CLR) for both temocapril and temocaprilat.
This comprehensive study design, incorporating both single-dose and repeated-dose assessments along with plasma and urinary measurements, provided a robust framework for evaluating age-related differences in the pharmacokinetics of temocapril. Such an approach is critical for informing evidence-based dosing strategies in diverse patient populations.
Key Pharmacokinetic Findings
The pharmacokinetic evaluation of temocapril and its active metabolite, temocaprilat, revealed several important findings regarding drug behavior in both young and elderly hypertensive patients. One of the most notable observations was that steady-state conditions were achieved within one week of once-daily dosing in both age groups. This indicates that temocapril does not exhibit prolonged or unexpected accumulation, and its pharmacokinetic profile remains predictable under repeated administration.
A key difference between the two populations emerged in the systemic exposure to temocaprilat, the pharmacologically active metabolite. Specifically, statistically significant increases in the area under the plasma concentration–time curve (AUC) and steady-state AUC (AUCss) were observed in elderly patients compared to younger individuals. These findings suggest that older patients experience higher overall exposure to temocaprilat, which may be attributed to age-related physiological changes, particularly reduced renal function. Since temocaprilat is primarily eliminated via the kidneys, diminished renal clearance in the elderly can lead to prolonged circulation and increased plasma concentrations.
In addition to changes in AUC, differences in renal clearance (CLR) were also identified for both temocapril and temocaprilat. Elderly subjects exhibited lower CLR values, further supporting the notion that renal elimination is less efficient in this population. This reduction in clearance contributes to the increased systemic exposure observed for the active metabolite. Despite these differences, other pharmacokinetic parameters—such as maximum plasma concentration (Cmax), time to reach maximum concentration (Tmax), and elimination half-life (t½)—did not show statistically significant variation between the two groups. This indicates that the rate of absorption and the initial distribution phase of the drug are largely unaffected by age.
Importantly, the parent compound, temocapril, demonstrated relatively consistent pharmacokinetic behavior across both age groups, reinforcing its role as a prodrug that is rapidly converted into temocaprilat. The clinical relevance of these findings lies in the balance between increased exposure and maintained tolerability. Although elderly patients showed higher AUC values for the active metabolite, the absence of major differences in other parameters suggests that the overall pharmacokinetic profile remains stable and manageable.
These results highlight the importance of considering age-related changes in drug metabolism and elimination, particularly for medications with active metabolites and renal excretion pathways. While the observed differences do not necessarily mandate dose adjustments, they provide valuable insight into how temocapril behaves in older patients and underscore the need for careful clinical monitoring.
Clinical Implications for Elderly Patients
The pharmacokinetic differences observed between young and elderly hypertensive patients receiving temocapril have important clinical implications, particularly in the context of safe and effective antihypertensive therapy. Although the study demonstrated increased systemic exposure to temocaprilat in elderly individuals—primarily reflected by higher AUC and reduced renal clearance—these changes were not accompanied by significant alterations in other key pharmacokinetic parameters such as peak concentration or time to peak. This suggests that, while drug elimination may be slower in older patients, the overall pharmacokinetic profile remains relatively stable and predictable.
From a clinical perspective, the absence of dramatic pharmacokinetic shifts indicates that routine dose adjustment of temocapril based solely on age may not be necessary. This is an important consideration, as overt dose reductions can potentially compromise therapeutic efficacy. However, the increased exposure to the active metabolite in elderly patients should not be overlooked. Even modest elevations in drug levels can enhance pharmacodynamic effects, especially in a population that is often more sensitive to blood pressure–lowering agents.
One of the most relevant clinical concerns in this context is the risk of first-dose hypotension, a well-documented phenomenon associated with ACE inhibitors. Elderly patients are particularly susceptible due to age-related physiological changes, including decreased baroreceptor sensitivity, reduced vascular compliance, and a higher likelihood of concomitant conditions such as volume depletion or polypharmacy. The elevated exposure to temocaprilat may further increase this risk, particularly at the initiation of therapy.
For this reason, while standard maintenance dosing may remain appropriate, a more cautious approach to treatment initiation is often recommended in elderly hypertensive patients. Starting with a lower initial dose and gradually titrating upward allows clinicians to monitor patient response and minimize adverse effects such as dizziness, syncope, or excessive blood pressure reduction. This individualized dosing strategy aligns with broader principles of geriatric pharmacotherapy, which emphasize “start low, go slow” to enhance safety without sacrificing efficacy.
